Pharma major Lupin Limited reported its financial performance for the quarter ending December 31, 2024. Lupin's consolidated net profit rose 39.5% year-on-year to Rs 855 crore during the quarter ended Dec. 31, 2024, in comparison to Rs 613 crore in the year-ago period.

During Q3 FY25, Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore in Q3 FY24. EBITDA up 33.6% to Rs 1,366 crore as compared to Rs 1,022 crore.

The rise in revenue was led by building scale in new products and were aided by higher PLI and export benefits. North America sales grew 12.3% year-on-year, accounting for 38% of global sales. The sequential growth in US sales was led by higher market share in Albuterol, as well as, sales ramp-up of both 25 mg and 50 mg versions of generic Myrbetriq.

India sales grew 11.9% year-on-year, led by strong growth in diabetes portfolio and accounted for 34% of global sales. Lupin launched 11 brands across diabetes, neuro/CNS in India.

Nilesh Gupta, Managing Director, Lupin Limited said “Our third-quarter results highlight our continued strength, with both revenue and EBITDA showing sustained growth. US revenues led by building scale in new products have been pivotal for our growth, supported by a strong nine-month performance from our India and EMEA regions. We look forward to maintaining this momentum in the ensuing quarters backed by growth in sales, commercial and operating efficiencies, and strong compliance.”

Lupin received approval for 6 ANDA from the U.S. FDA in the quarter. Cumulative ANDA filings with the U.S. FDA stand at 430 as of December 31, 2024, with the Company having received 334 approvals to date.

The Company now has 49 First-to-File (FTF) filings including 17 exclusive FTF opportunities. Cumulative U.S. DMF filings stand at 156 as of December 31, 2024.